CRDF Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: July 14, 2026 , by PACE GARY W .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director | Buy | 687,285 | $1.46 | $1000.0K | 2,043,661 | |
| Mohindru Mani | Chief Executive Officer | Buy | 34,364 | $1.46 | $50.0K | 59,067 | |
| PACE GARY W | Director | Buy | 30,000 | $1.22 | $36.6K | 1,356,376 | |
| Mohindru Mani | Chief Executive Officer | Buy | 24,703 | $1.21 | $29.9K | 24,703 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.